House



LEGISLATIVE ACTION

Senate	
Comm: RCS	
03/25/2019	

The Committee on Health Policy (Bean) recommended the following: Senate Amendment (with title amendment) Delete everything after the enacting clause and insert: Section 1. Section 381.02035, Florida Statutes, is created to read: <u>381.02035 Canadian Prescription Drug Importation Program.-</u> (1) PROGRAM ESTABLISHED.-The Agency for Health Care <u>Administration shall establish a program for the importation of</u> <u>safe and effective prescription drugs from Canada which have the</u> highest potential for cost savings to the state.

1 2 3

4

5

6

7

8

9

10

9	58184
---	-------

12	(2) DEFINITIONSAs used in this section, the term:
13	(a) "Agency" means the Agency for Health Care
14	Administration.
15	(b) "Canadian supplier" means a manufacturer, wholesale
16	distributor, or pharmacy appropriately licensed or permitted
17	under Canadian law to manufacture, distribute, or dispense
18	prescription drugs.
19	(c) "Drug" or "prescription drug" has the same meaning as
20	"prescription drug" in s. 499.003.
21	(d) "Federal Act" means the Federal Food, Drug, and
22	Cosmetic Act, 21 U.S.C. ss. 301 et seq.; 52 Stat. 1040 et seq.
23	as amended by the Drug Quality and Security Act, 21 U.S.C. 351
24	et seq.
25	(e) "Importer" means a wholesale distributor, pharmacy, or
26	pharmacist importing prescription drugs into this state under
27	the program.
28	(f) "Pharmacist" means a person who holds an active and
29	unencumbered license to practice pharmacy pursuant to chapter
30	465.
31	(g) "Program" means the Canadian Prescription Drug
32	Importation Program.
33	(h) "Track-and-trace" means the product-tracing process for
34	the components of the pharmaceutical distribution supply chain
35	as described in Title II of the Drug Quality and Security Act,
36	Drug Supply Chain Security Act, 21 U.S.C. 351 et seq.
37	(i) "Vendor" means the entity contracted by the agency to
38	manage specified functions of the program.
39	(3) ELIGIBLE CANADIAN SUPPLIERS.—A Canadian supplier may
40	export drugs into this state under the program if the supplier

#### 958184

meets all of the following requirements: 41 42 (a) Complies fully with relevant Canadian federal and 43 provincial laws and regulations. 44 (b) Complies fully with the Federal Act, including all 45 other state and federal law and regulations relating to the 46 track-and-trace requirements at the package level. 47 (c) Submits evidence at time of contract award and 48 throughout the contract term of a surety bond or comparable 49 security arrangement from this state or any other state in the 50 United States in the minimum amount of \$1 million. The agency 51 shall reevaluate and adjust the amount of the bond annually, 52 based on program volume. The surety bond or comparable security 53 arrangement must include the State of Florida as a beneficiary. 54 In lieu of the surety bond, the supplier may provide a 55 comparable security arrangement such as an irrevocable letter of 56 credit or a deposit into a trust account or financial 57 institution which includes the State of Florida as a 58 beneficiary. The purposes of the bond or other security 59 arrangements for the program are to: 60 1. Ensure payment of any administrative penalties imposed 61 by the agency or any other state agency under the contract when 62 the supplier fails to pay within 30 days after assessment; 63 2. Ensure performance of contractual and statutory 64 obligations by the supplier through use of a bond or other 65 comparable security arrangements to receive payment of any other 66 costs or fees incurred by the agency, the state, or other 67 entities acting on behalf of the state if the supplier is non-68 compliant with its contractual and statutory obligations. If the 69 supplier is assessed a penalty under the program and fails to

958184

70	pay within 30 days after that assessment, the agency, the state,
71	or an entity acting on behalf of the state may file a claim for
72	reimbursement against the bond or other comparable security
73	arrangement; and
74	3. Allow for claims to be made against the bond or other
75	comparable security arrangements for up to 1 year after the
76	supplier's contract under the program has ended with the agency
77	or the state, the supplier's license is no longer valid, or the
78	program has ended, whichever occurs last.
79	
80	A surety bond or other comparable security arrangement is
81	required regardless of the time of bid or negotiation process
82	used by the agency or the type of final contract or agreement
83	executed for services.
84	(d) Is identified by the vendor as eligible to participate
85	in the program.
86	(e) Submits evidence at the time of contract award and
87	throughout the contract term of a surety bond or comparable
88	security arrangement from this state or any other state in the
89	United States in the minimum amount of \$1 million. The agency
90	shall reevaluate and adjust the amount of the bond annually,
91	based on program volume. The surety bond or comparable security
92	arrangement must include the State of Florida as a beneficiary.
93	In lieu of the surety bond, the supplier may provide a
94	comparable security arrangement such as an irrevocable letter of
95	credit or a deposit into a trust account or financial
96	institution which includes the State of Florida as a
97	beneficiary. The purposes of the bond or other security
98	arrangements for the program are to:
	1

Page 4 of 18

### 958184

99	1. Indemnify the supplier in the event that any civil or
100	criminal legal action is brought by the state, the agency, any
101	other state agency, or private individuals or entities against
102	the supplier because of the supplier's failure to perform under
103	the contract, including, but not limited to, causes of actions
104	for personal injury, negligence, and wrongful death;
105	2. Ensure payment by the supplier of legal judgements and
106	claims that have been awarded to the state, the agency, other
107	entities acting on behalf of the state, individuals, or
108	organizations if the supplier is assessed a final judgement or
109	other monetary penalty in a court of law for a civil or criminal
110	action related to participation in the program. The bond or
111	comparable security arrangement may be accessed if the supplier
112	fails to pay any judgement or claim within 60 days after final
113	judgement; and
114	3. Allow for civil and criminal litigation claims to be
115	made against the bond or other comparable security arrangements
116	for up to 1 year after the supplier's contract under the program
117	has ended with the agency or the state, the supplier's license
118	is no longer valid, or the program has ended, whichever occurs
119	last.
120	(4) ELIGIBLE IMPORTERS
121	(a) The following entities or persons may import
122	prescription drugs from a Canadian supplier under the program:
123	1. A wholesale distributor.
124	2. A pharmacy.
125	3. A pharmacist.
126	(b) An eligible importer must meet all of the following
127	requirements at time of contract award and throughout the

Page 5 of 18

### 958184

128 contract term: 129 1. Register with the vendor before importing drugs into the 130 state under the program and be deemed in compliance with all 131 requirements, including any relevant provisions of the Federal 132 Act. 2. Submit evidence at time of contract award and throughout 133 134 the contract term of a surety bond or other comparable security 135 arrangement from this state or any other state in the United 136 States in the amount of \$1 million. The surety bond or 137 comparable security arrangement must include the State of Florida as a beneficiary. In lieu of the surety bond, the 138 139 supplier may provide a comparable security agreement such as an 140 irrevocable letter of credit or a deposit into a trust account 141 or financial institution which includes the State of Florida as 142 a beneficiary, payable to the State of Florida. The purposes of 143 the bond or other security arrangements for the program are to: 144 a. Ensure payment of any administrative penalties imposed 145 by the agency or any other state agency under the contract when 146 the importer fails to pay within 30 days after assessment; 147 b. Ensure performance of contractual and statutory 148 obligations by the importer through use of a bond or other 149 comparable security arrangements to receive payment of any other 150 costs or fees incurred by the agency, the state, or other 151 entities acting on behalf of the state if the importer is non-152 compliant with its contractual and statutory obligations. If the 153 importer is assessed a penalty under the program and fails to 154 pay within 30 days after that assessment, the agency, the state, 155 or an entity acting on behalf of the state may file a claim for 156 reimbursement against the bond or other comparable security

### 958184

157 arrangement; and 158 c. Allow for claims to be made against the bond or other 159 comparable security arrangements for up to 1 year after the importer's contract under the program has ended with the agency 160 161 or the state, the importer's license is no longer valid, or the 162 program has ended, whichever occurs last. 163 164 A surety bond or comparable document is required regardless of the time of bid or negotiation process used by the agency or the 165 166 type of final contract or agreement executed for services. 167 (c) Submits evidence at the time of contract award and 168 throughout the contract term of a surety bond or comparable 169 security arrangement from this state or any other state in the 170 United States in the minimum amount of \$1 million. The agency 171 shall reevaluate and adjust the amount of the bond annually, 172 based on program volume. The surety bond or comparable security 173 arrangement must include the State of Florida as a beneficiary. In lieu of the surety bond, the supplier may provide a 174 175 comparable security agreement such as an irrevocable letter of 176 credit or a deposit into a trust account or financial 177 institution which includes the State of Florida as a 178 beneficiary, payable to the State of Florida. The purposes of 179 the bond or other security arrangements for the program are to: 180 1. Ensure participation of the supplier in any civil or 181 criminal legal action by the state, the agency, any other state 182 agency, or private individuals or entities against the supplier 183 because of the supplier's failure to perform under the contract, 184 including, but not limited to causes of actions for personal 185 injury, negligence, and wrongful death;

Page 7 of 18

958184

186	2. Ensure payment by the supplier through the use of a bond
187	or other comparable security arrangements of legal judgements
188	and claims that have been awarded to the agency, the state,
189	other entities acting on behalf of the state, individuals, or
190	organizations if the supplier is assessed a final judgement or
191	other monetary penalty in a court of law for a civil or criminal
192	action under the program. The bond or comparable security
193	arrangement will be accessed if the supplier fails to pay any
194	judgement or claim within 60 days after final judgement; and
195	3. Allow for civil and criminal litigation claims to be
196	made against the bond or other comparable security arrangements
197	for up to 1 year after the supplier's contract under the program
198	has ended with the agency or the state, the supplier's license
199	is no longer valid, or the program has ended, whichever occurs
200	last.
201	(5) IMPORTATION PROCESS.—
202	(a) The agency shall contract with a vendor to provide
203	services under the program. The vendor must submit evidence of a
204	surety bond with any bid or initial contract negotiation
205	documents and maintain documentation of evidence of such a bond
206	with the agency throughout the throughout the contract term of a
207	surety bond from this state or any other state in the United
208	States in the same amount of \$1 million. The surety bond or
209	comparable security arrangement must include the State of
210	Florida as a beneficiary. In lieu of the surety bond, the
211	supplier may provide a comparable security agreement such as an
212	irrevocable letter of credit or a deposit into a trust account
213	or financial institution which includes the State of Florida as
214	a beneficiary, payable to the State of Florida. The purposes of

Page 8 of 18

215	the bond or other security arrangements for the program are to:
216	1. Ensure payment of any administrative penalties imposed
217	by the agency or any other state agency under the contract when
218	the vendor fails to pay within 30 days after assessment;
219	2. Ensure performance of contractual and statutory
220	obligations by the vendor through use of a surety bond or other
221	comparable security arrangements to receive payment of any other
222	costs or fees incurred by the agency, the state, or other
223	entities acting on behalf of the state if the vendor is non-
224	compliant with its contractual and statutory obligations. If the
225	vendor is assessed a penalty under the program and fails to pay
226	within 30 days after that assessment, the agency, the state, or
227	an entity acting on behalf of the state may file a claim for
228	reimbursement against the bond or other comparable security
229	arrangement; and
230	3. Allow for claims to be made against the bond or other
231	comparable security arrangements for up to 1 year after the
232	vendor's contract under the program has ended with the agency or
233	the state, the importer's license is no longer valid, or the
234	program has ended, whichever occurs last.
235	
236	A surety bond or comparable document is required regardless of
237	the time of bid or negotiation process used by the agency or the
238	type of final contract or agreement executed for services.
239	(b) Submits evidence at the time of contract award and
240	throughout the contract term of a surety bond or comparable
241	security arrangement from this state or any other state in the
242	United States in the minimum amount of \$1 million. The agency
243	shall reevaluate and adjust the amount of the bond annually,

244	based on program volume. The surety bond or comparable security
245	arrangement must include the State of Florida as a beneficiary.
246	In lieu of the surety bond, the supplier may provide a
247	comparable security arrangement such as an irrevocable letter of
248	credit or a deposit into a trust account or financial
249	institution which names the State of Florida as a beneficiary.
250	The purposes of the bond or other security arrangements for the
251	program are to:
252	1. Ensure participation of the vendor in any civil or
253	criminal legal action by the state, the agency, any other state
254	agency, or private individuals or entities against the vendor
255	because of the vendor's failure to perform under the contract,
256	including, but not limited to causes of actions for personal
257	injury, negligence, and wrongful death;
258	2. Ensure payment by the vendor through the use of a bond
259	or other comparable security arrangements of legal judgements
260	and claims that have been awarded to the agency, the state,
261	other entities acting on behalf of the state, individuals, or
262	organizations if the vendor is assessed a final judgement or
263	other monetary penalty in a court of law for a civil or criminal
264	action under the program. The bond or comparable security
265	arrangement will be accessed if the vendor fails to pay any
266	judgement or claim within 60 days after final judgement; and
267	3. Allow for civil and criminal litigation claims to be
268	made against the bond or other comparable security arrangements
269	for up to 1 year after the vendor's contract under the program
270	has ended with the agency or the state, the vendor's license is
271	no longer valid, or the program has ended, whichever occurs
272	last.
	I

958184

273	(c) The vendor shall provide all of the following services
274	at a minimum:
275	1. Develop a list every 3 month of drugs that have the
276	highest potential for cost savings to the state if imported from
277	Canada. In developing the list, the vendor shall consider, at a
278	minimum, which drugs will provide the greatest cost savings to
279	the state, including drugs for which there are shortages,
280	specialty drugs, and high-volume drugs. The agency may direct
281	the vendor to revise the list, as necessary.
282	2. Identify Canadian suppliers that are in full compliance
283	with relevant Canadian federal and provincial laws and
284	regulations and the Federal Act and who have agreed to export
285	drugs identified on the list. The vendor must verify that such
286	Canadian suppliers meet all of the requirements of the program
287	and will export drugs at prices that will provide cost savings
288	to the state while meeting or exceeding the track-and-trace
289	federal and state laws and regulations.
290	3. Contract with such eligible Canadian suppliers, or
291	facilitate contracts between eligible importers and Canadian
292	suppliers, to import drugs under the program.
293	4. Maintain a listing of all registered importers that
294	participate in the program.
295	5. Ensure compliance with Title II of the federal Drug
296	Quality and Security Act P.L. 113-54 by all suppliers, importers
297	and other distributors and participants in the program.
298	6. Assist the agency with the annual report as required in
299	subsection (12) and provide any information requested by the
300	agency for such report on a timely basis.
301	(d) The profit margin and administrative fees of any

Page 11 of 18

COMMITTEE AMENDMENT

Florida Senate - 2019 Bill No. SB 1528

# 958184

302	participating wholesaler, pharmacy, or pharmacist on imported
303	drug products is limited to a maximum amount as specified
304	annually in the General Appropriations Act.
305	(6) ELIGIBLE PRESCRIPTION DRUGSEligible importers may
306	import a drug from an eligible Canadian supplier if:
307	(a) The drug meets the United States Food and Drug
308	Administration's standards related to safety, effectiveness,
309	misbranding, and adulteration;
310	(b) Importing the drug would not violate the patent laws of
311	the United States;
312	(c) Importing the drug is expected to generate cost
313	savings; and
314	(d) The drug is not:
315	1. A controlled substance as defined in 21 U.S.C. s. 802;
316	2. A biological product as defined in 42 U.S.C. s. 262;
317	3. An infused drug;
318	4. An intravenously injected drug;
319	5. A drug that is inhaled during surgery; or
320	6. A drug that is a parenteral drug, the importation of
321	which is determined by the United States Secretary of Health and
322	Human Services to pose a threat to the public health.
323	(7) DISTRIBUTION REQUIREMENTSEligible Canadian suppliers
324	and importers participating under the program:
325	(a) Must comply with the tracking and tracing requirements
326	of 21 U.S.C. ss. 360eee et seq.
327	(b) May not distribute, dispense, or sell drugs imported
328	under the program outside of the program or outside of this
329	state.
330	(8) PRESCRIPTION DRUG SUPPLY CHAIN DOCUMENTATION

Page 12 of 18

958184

331	(a) The vendor shall ensure the safety and quality of drugs
332	imported under the program. The vendor shall:
333	1. For an initial imported shipment, ensure that each batch
334	of the drug in the shipment is statistically sampled and tested
335	for authenticity and degradation in a manner consistent with the
336	Federal Act.
337	2. For any subsequent imported shipment, ensure that a
338	statistically valid sample of the shipment was tested for
339	authenticity and degradation in a manner consistent with the
340	Federal Act.
341	3. Certify that the drug:
342	a. Is approved for marketing in the United States and is
343	not adulterated or misbranded; and
344	b. Meets all of the labeling requirements under 21 U.S.C.
345	<u>s. 352.</u>
346	4. Maintain qualified laboratory records, including
347	complete data derived from all tests necessary to ensure that
348	the drug is in compliance with the requirements of this section.
349	5. Maintain documentation demonstrating that the testing
350	required by this section was conducted at a qualified laboratory
351	in accordance with the Federal Act and any other applicable
352	federal and state laws and regulations governing laboratory
353	qualifications.
354	(b) All testing required by this section must be conducted
355	in a qualified laboratory that meets the standards under the
356	Federal Act and any other applicable federal and state laws and
357	regulations governing laboratory qualifications for drug
358	testing.
359	(c) The vendor shall maintain information and documentation

Page 13 of 18

361(d) A participating importer must submit the all of362following information to the vendor:3631. The name and quantity of the active ingredient of the364drug.3652. A description of the dosage form of the drug.3663. The date on which the drug is received.3674. The quantity of the drug that is received.3685. The point of origin and destination of the drug.3706. The price paid by the importer for the drug.371following information and documentation to the vendor specifying372all of the following:3731. The original source of the drug, including:374a. The name of the manufacturer of the drug.375b. The date on which the drug was manufactured.376c. The location (country, state or province, and city)377where the drug was manufactured.3783. The quantity of the drug which is shipped.3793. The quantity of the drug which is shipped.3794. The quantity of the drug which is shipped.3714. The quantity of each lot of the drug originally received372and from which source.3735. The lot or control number and the batch number assigned374and from which source.3755. The lot or control number and the batch number assigned376to the drug by the manufacturer.377(f) The agency may require that the vendor collect any378other information necessary to ensure the protection of the379yublic health.<	360	submitted under this section for a period of at least 7 years.
363       1. The name and quantity of the active ingredient of the         364       drug.         365       2. A description of the dosage form of the drug.         366       3. The date on which the drug is received.         367       4. The quantity of the drug that is received.         368       5. The point of origin and destination of the drug.         369       6. The price paid by the importer for the drug.         370       (e) A participating Canadian supplier must submit the         371       following information and documentation to the vendor specifying         372       all of the following:         373       1. The original source of the drug, including:         374       a. The name of the manufacturer of the drug.         375       b. The date on which the drug was manufactured.         376       c. The location (country, state or province, and city)         377       where the drug was manufactured.         378       2. The date on which the drug is shipped.         379       3. The quantity of each lot of the drug originally received         381       4. The quantity of each lot of the drug originally received         381       and from which source.         382       5. The lot or control number and the batch number assigned         383       to the drug by the man	361	(d) A participating importer must submit the all of
364drug.3652. A description of the dosage form of the drug.3663. The date on which the drug is received.3674. The quantity of the drug that is received.3685. The point of origin and destination of the drug.3696. The price paid by the importer for the drug.370(e) A participating Canadian supplier must submit the371following information and documentation to the vendor specifying372all of the following:3731. The original source of the drug, including:374a. The name of the manufacturer of the drug.375b. The date on which the drug was manufactured.376c. The location (country, state or province, and city)377where the drug was manufactured.3782. The date on which the drug is shipped.3804. The quantity of each lot of the drug originally received381and from which source.3825. The lot or control number and the batch number assigned383to the drug by the manufacturer.384(f) The agency may require that the vendor collect any385other information necessary to ensure the protection of the386public health.387(9) IMMEDIATE SUSPENSIONThe agency shall immediately	362	following information to the vendor:
3652. A description of the dosage form of the drug.3663. The date on which the drug is received.3674. The quantity of the drug that is received.3685. The point of origin and destination of the drug.3696. The price paid by the importer for the drug.370(e) A participating Canadian supplier must submit the371following information and documentation to the vendor specifying372all of the following:3731. The original source of the drug, including:374a. The name of the manufacturer of the drug.375b. The date on which the drug was manufactured.376c. The location (country, state or province, and city)377where the drug was manufactured.3782. The date on which the drug is shipped.3793. The quantity of each lot of the drug originally received381and from which source.3825. The lot or control number and the batch number assigned383to the drug by the manufacturer.384(f) The agency may require that the vendor collect any385other information necessary to ensure the protection of the386(9) IMMEDIATE SUSPENSIONThe agency shall immediately	363	1. The name and quantity of the active ingredient of the
3663. The date on which the drug is received.3674. The quantity of the drug that is received.3685. The point of origin and destination of the drug.3696. The price paid by the importer for the drug.370(e) A participating Canadian supplier must submit the371following information and documentation to the vendor specifying372all of the following:3731. The original source of the drug, including:374a. The name of the manufacturer of the drug.375b. The date on which the drug was manufactured.376c. The location (country, state or province, and city)377where the drug was manufactured.3782. The date on which the drug is shipped.3793. The quantity of the drug which is shipped.3804. The quantity of each lot of the drug originally received381and from which source.3825. The lot or control number and the batch number assigned383to the drug by the manufacturer.384(f) The agency may require that the vendor collect any385other information necessary to ensure the protection of the386public health.387(9) IMMEDIATE SUSPENSIONThe agency shall immediately	364	drug.
3674. The quantity of the drug that is received.3685. The point of origin and destination of the drug.3696. The price paid by the importer for the drug.370(e) A participating Canadian supplier must submit the371following information and documentation to the vendor specifying372all of the following:3731. The original source of the drug, including:374a. The name of the manufacturer of the drug.375b. The date on which the drug was manufactured.376c. The location (country, state or province, and city)377where the drug was manufactured.3782. The date on which the drug is shipped.3793. The quantity of each lot of the drug originally received381and from which source.3825. The lot or control number and the batch number assigned383to the drug by the manufacturer.384(f) The agency may require that the vendor collect any385other information necessary to ensure the protection of the386(9) IMMEDIATE SUSPENSIONThe agency shall immediately	365	2. A description of the dosage form of the drug.
3685. The point of origin and destination of the drug.3696. The price paid by the importer for the drug.370(e) A participating Canadian supplier must submit the371following information and documentation to the vendor specifying372all of the following:3731. The original source of the drug, including:374a. The name of the manufacturer of the drug.375b. The date on which the drug was manufactured.376c. The location (country, state or province, and city)377where the drug was manufactured.3782. The date on which the drug is shipped.3793. The quantity of the drug which is shipped.3804. The quantity of each lot of the drug originally received381and from which source.3825. The lot or control number and the batch number assigned383to the drug by the manufacturer.384(f) The agency may require that the vendor collect any385other information necessary to ensure the protection of the386(9) IMMEDIATE SUSPENSIONThe agency shall immediately	366	3. The date on which the drug is received.
3696. The price paid by the importer for the drug. (e) A participating Canadian supplier must submit the371following information and documentation to the vendor specifying372all of the following:3731. The original source of the drug, including:374a. The name of the manufacturer of the drug.375b. The date on which the drug was manufactured.376c. The location (country, state or province, and city)377where the drug was manufactured.3782. The date on which the drug is shipped.3793. The quantity of the drug which is shipped.3804. The quantity of each lot of the drug originally received381and from which source.3825. The lot or control number and the batch number assigned383to the drug by the manufacturer.384(f) The agency may require that the vendor collect any other information necessary to ensure the protection of the386(9) IMMEDIATE SUSPENSIONThe agency shall immediately	367	4. The quantity of the drug that is received.
370(e) A participating Canadian supplier must submit the371following information and documentation to the vendor specifying372all of the following:3731. The original source of the drug, including:374a. The name of the manufacturer of the drug.375b. The date on which the drug was manufactured.376c. The location (country, state or province, and city)377where the drug was manufactured.3782. The date on which the drug is shipped.3793. The quantity of the drug which is shipped.3804. The quantity of each lot of the drug originally received381and from which source.3825. The lot or control number and the batch number assigned383to the drug by the manufacturer.384(f) The agency may require that the vendor collect any385other information necessary to ensure the protection of the386public health.387(9) IMMEDIATE SUSPENSIONThe agency shall immediately	368	5. The point of origin and destination of the drug.
In the second se	369	6. The price paid by the importer for the drug.
<ul> <li>all of the following:</li> <li>1. The original source of the drug, including:</li> <li>a. The name of the manufacturer of the drug.</li> <li>b. The date on which the drug was manufactured.</li> <li>c. The location (country, state or province, and city)</li> <li>where the drug was manufactured.</li> <li>2. The date on which the drug is shipped.</li> <li>3. The quantity of the drug which is shipped.</li> <li>3. The quantity of each lot of the drug originally received</li> <li>and from which source.</li> <li>5. The lot or control number and the batch number assigned</li> <li>to the drug by the manufacturer.</li> <li>(f) The agency may require that the vendor collect any</li> <li>other information necessary to ensure the protection of the</li> <li>public health.</li> <li>(9) IMMEDIATE SUSPENSIONThe agency shall immediately</li> </ul>	370	(e) A participating Canadian supplier must submit the
3731. The original source of the drug, including:374a. The name of the manufacturer of the drug.375b. The date on which the drug was manufactured.376c. The location (country, state or province, and city)377where the drug was manufactured.3782. The date on which the drug is shipped.3793. The quantity of the drug which is shipped.3804. The quantity of each lot of the drug originally received381and from which source.3825. The lot or control number and the batch number assigned383to the drug by the manufacturer.384(f) The agency may require that the vendor collect any385other information necessary to ensure the protection of the386public health.387(9) IMMEDIATE SUSPENSIONThe agency shall immediately	371	following information and documentation to the vendor specifying
<ul> <li>374 <ul> <li>a. The name of the manufacturer of the drug.</li> </ul> </li> <li>375 <ul> <li>b. The date on which the drug was manufactured.</li> <li>c. The location (country, state or province, and city)</li> </ul> </li> <li>377 <ul> <li>where the drug was manufactured.</li> </ul> </li> <li>378 <ul> <li>2. The date on which the drug is shipped.</li> </ul> </li> <li>379 <ul> <li>3. The quantity of the drug which is shipped.</li> </ul> </li> <li>380 <ul> <li>4. The quantity of each lot of the drug originally received</li> </ul> </li> <li>381 <ul> <li>and from which source.</li> </ul> </li> <li>382 <ul> <li>5. The lot or control number and the batch number assigned</li> </ul> </li> <li>383 <ul> <li>to the drug by the manufacturer.</li> </ul> </li> <li>384 <ul> <li>(f) The agency may require that the vendor collect any</li> <li>other information necessary to ensure the protection of the</li> </ul> </li> <li>386 <ul> <li>public health.</li> <li>387</li> <li>(9) IMMEDIATE SUSPENSIONThe agency shall immediately</li> </ul> </li> </ul>	372	all of the following:
375b. The date on which the drug was manufactured.376c. The location (country, state or province, and city)377where the drug was manufactured.3782. The date on which the drug is shipped.3793. The quantity of the drug which is shipped.3804. The quantity of each lot of the drug originally received381and from which source.3825. The lot or control number and the batch number assigned383to the drug by the manufacturer.384(f) The agency may require that the vendor collect any385other information necessary to ensure the protection of the386public health.387(9) IMMEDIATE SUSPENSIONThe agency shall immediately	373	1. The original source of the drug, including:
<ul> <li>376</li> <li>376</li> <li>c. The location (country, state or province, and city)</li> <li>377</li> <li>378</li> <li>378</li> <li>2. The date on which the drug is shipped.</li> <li>379</li> <li>3. The quantity of the drug which is shipped.</li> <li>380</li> <li>4. The quantity of each lot of the drug originally received</li> <li>381</li> <li>and from which source.</li> <li>382</li> <li>5. The lot or control number and the batch number assigned</li> <li>383</li> <li>40</li> <li>40</li> <li>41</li> <li>41</li> <li>42</li> <li>43</li> <li>44</li> <li>45</li> <li>46</li> <li>46</li> <li>47</li> <li>46</li> <li>47</li> <li>47</li> <li>47</li> <li>48</li> <li>49</li> <li>49</li> <li>49</li> <li>40</li> <li>40</li></ul>	374	a. The name of the manufacturer of the drug.
377 where the drug was manufactured. 378 <u>2. The date on which the drug is shipped.</u> 379 <u>3. The quantity of the drug which is shipped.</u> 380 <u>4. The quantity of each lot of the drug originally received</u> 381 <u>and from which source.</u> 382 <u>5. The lot or control number and the batch number assigned</u> 383 <u>to the drug by the manufacturer.</u> 384 <u>(f) The agency may require that the vendor collect any</u> 385 <u>other information necessary to ensure the protection of the</u> 386 <u>(9) IMMEDIATE SUSPENSIONThe agency shall immediately</u>	375	b. The date on which the drug was manufactured.
<ul> <li>378</li> <li>2. The date on which the drug is shipped.</li> <li>379</li> <li>3. The quantity of the drug which is shipped.</li> <li>380</li> <li>4. The quantity of each lot of the drug originally received</li> <li>381</li> <li>and from which source.</li> <li>382</li> <li>5. The lot or control number and the batch number assigned</li> <li>383</li> <li>to the drug by the manufacturer.</li> <li>384</li> <li>(f) The agency may require that the vendor collect any</li> <li>385</li> <li>other information necessary to ensure the protection of the</li> <li>public health.</li> <li>387</li> <li>(9) IMMEDIATE SUSPENSIONThe agency shall immediately</li> </ul>	376	c. The location (country, state or province, and city)
<ul> <li>379</li> <li>3. The quantity of the drug which is shipped.</li> <li>380</li> <li>4. The quantity of each lot of the drug originally received</li> <li>381</li> <li>and from which source.</li> <li>382</li> <li>5. The lot or control number and the batch number assigned</li> <li>383</li> <li>to the drug by the manufacturer.</li> <li>384</li> <li>(f) The agency may require that the vendor collect any</li> <li>385</li> <li>other information necessary to ensure the protection of the</li> <li>386</li> <li><u>public health.</u></li> <li>387</li> <li>(9) IMMEDIATE SUSPENSIONThe agency shall immediately</li> </ul>	377	where the drug was manufactured.
<ul> <li>380</li> <li><u>4. The quantity of each lot of the drug originally received</u></li> <li>381</li> <li><u>and from which source.</u></li> <li>382</li> <li><u>5. The lot or control number and the batch number assigned</u></li> <li>383</li> <li><u>to the drug by the manufacturer.</u></li> <li>384</li> <li><u>(f) The agency may require that the vendor collect any</u></li> <li><u>385 other information necessary to ensure the protection of the</u></li> <li><u>386 public health.</u></li> <li><u>387 (9) IMMEDIATE SUSPENSIONThe agency shall immediately</u></li> </ul>	378	2. The date on which the drug is shipped.
381 <u>and from which source.</u> 382 <u>5. The lot or control number and the batch number assigned</u> 383 to the drug by the manufacturer. 384 <u>(f) The agency may require that the vendor collect any</u> 385 <u>other information necessary to ensure the protection of the</u> 386 <u>public health.</u> 387 <u>(9) IMMEDIATE SUSPENSION.—The agency shall immediately</u>	379	3. The quantity of the drug which is shipped.
382 <u>5. The lot or control number and the batch number assigned</u> 383 <u>to the drug by the manufacturer.</u> 384 <u>(f) The agency may require that the vendor collect any</u> 385 <u>other information necessary to ensure the protection of the</u> 386 <u>public health.</u> 387 <u>(9) IMMEDIATE SUSPENSION.—The agency shall immediately</u>	380	4. The quantity of each lot of the drug originally received
383 to the drug by the manufacturer. 384 (f) The agency may require that the vendor collect any 385 other information necessary to ensure the protection of the 386 public health. 387 (9) IMMEDIATE SUSPENSION.—The agency shall immediately	381	and from which source.
384 <u>(f) The agency may require that the vendor collect any</u> 385 <u>other information necessary to ensure the protection of the</u> 386 <u>public health.</u> 387 <u>(9) IMMEDIATE SUSPENSIONThe agency shall immediately</u>	382	5. The lot or control number and the batch number assigned
385other information necessary to ensure the protection of the386public health.387(9) IMMEDIATE SUSPENSION.—The agency shall immediately	383	to the drug by the manufacturer.
<pre>386 public health. 387 (9) IMMEDIATE SUSPENSION.—The agency shall immediately</pre>	384	(f) The agency may require that the vendor collect any
387 (9) IMMEDIATE SUSPENSION.—The agency shall immediately	385	other information necessary to ensure the protection of the
	386	public health.
388 suspend the importation of a specific drug or the importation of	387	(9) IMMEDIATE SUSPENSION The agency shall immediately
	388	suspend the importation of a specific drug or the importation of

958184

389	drugs by a specific importer if it discovers that any drug or
390	activity is in violation of this section or any federal or state
391	law or regulation. The agency may revoke the suspension if,
392	after conducting an investigation, it determines that the public
393	is adequately protected from counterfeit or unsafe drugs being
394	imported into the state.
395	(10) FEDERAL APPROVALBy July 1, 2020, the agency shall
396	submit a request to the United States Secretary of Health and
397	Human Services for approval of the program under 21 U.S.C. s.
398	384(1). At a minimum, the request must do all of the following:
399	(a) Describe the agency's plan for operating the program.
400	(b) Demonstrate how the drugs imported into the state under
401	the program will meet the applicable federal and state standards
402	for safety and effectiveness.
403	(c) Demonstrate how the drugs imported into the state under
404	the program will comply with federal tracing procedures.
405	(d) Include a list of proposed drugs that have the highest
406	potential for cost savings to the state through importation at
407	the time that the request is submitted.
408	(e) Estimate the total cost savings attributable to the
409	program.
410	(f) Provide the costs of program implementation to the
411	state.
412	(g) Include a list of potential Canadian suppliers from
413	which the state would import drugs and demonstrate that the
414	suppliers are in full compliance with relevant Canadian federal
415	and provincial laws and regulations as well as all applicable
416	federal and state laws and regulations.
417	(11) NOTIFICATION OF FEDERAL APPROVALUpon receipt of

Page 15 of 18

958184

418	federal approval of the program, the agency shall notify the
419	President of the Senate, the Speaker of the House of
420	Representatives, and the relevant committees of the Senate and
421	the House of Representatives. The program may not be implemented
422	until the Legislature approves the program as authorized by the
423	federal government. As part of its review process for
424	implementation approval, the Legislature shall consider the
425	estimated cost savings to the state and whether the program has
426	met the required safety standards.
427	(12) ANNUAL REPORTBy December 1 of each year, the agency
428	shall submit a report to the Governor, the President of the
429	Senate, and the Speaker of the House of Representatives on the
430	operation of the program during the previous fiscal year. The
431	report must include, at a minimum:
432	(a) A list of the drugs that were imported under the
433	program;
434	(b) The number of participating entities;
435	(c) The number of prescriptions dispensed through the
436	program;
437	(d) The estimated cost savings during the previous fiscal
438	year and to date in the program;
439	(e) A description of the methodology used to determine
440	which drugs should be included; and
441	(f) Documentation of how the program ensures the following
442	criteria:
443	1. Canadian suppliers participating in the program are of
444	high quality, high performance, and in full compliance with
445	relevant Canadian federal and provincial laws and regulations as
446	well as all United States and Florida laws and regulations;

Page 16 of 18

958184

447	2. Drugs imported under the program are not shipped, sold,
448	or dispensed outside of the state or the program once in the
449	possession of the importer;
450	3. Drugs imported under the program are unadulterated,
451	potent, and safe;
452	4. The program does not put consumers at a higher health
453	and safety risk than if the consumer did not participate; and
454	5. The program provides cost savings to the state.
455	(13) RULEMAKINGThe agency may adopt rules necessary to
456	implement this section.
457	Section 2. This act shall take effect July 1, 2019.
458	
459	======================================
460	And the title is amended as follows:
461	Delete everything before the enacting clause
462	and insert:
463	A bill to be entitled
464	An act relating to the Canadian Prescription Drug
465	Importation Program; creating s. 381.02035, F.S.;
466	requiring the Agency for Health Care Administration to
467	establish the Canadian Prescription Drug Importation
468	Program; defining terms; authorizing a Canadian
469	supplier to export drugs into this state under the
470	program under certain circumstances; providing
471	eligibility criteria and requirements for drug
472	importers; requiring the agency to contract with a
473	vendor to facilitate wholesale prescription drug
474	importation under the program; providing
475	responsibilities for the vendor; providing eligibility

Page 17 of 18

COMMITTEE AMENDMENT

Florida Senate - 2019 Bill No. SB 1528



476 criteria for prescription drugs, Canadian suppliers, 477 and importers under the program; requiring 478 participating Canadian suppliers and importers to 479 comply with specified federal requirements for 480 distributing prescription drugs imported under the 481 program; prohibiting Canadian suppliers and importers 482 from distributing, dispensing, or selling prescription 483 drugs imported under the program outside the state; 484 providing certain documentation requirements; 485 requiring the agency to suspend the importation of 486 drugs in violation of this section or any federal or 487 state law or regulation; authorizing the agency to 488 revoke the suspension under certain circumstances; 489 requiring the agency to request federal approval of 490 the program; requiring the request to include certain 491 information; requiring the agency to begin operating 492 the program within a specified timeframe after 493 receiving federal approval; requiring the agency, in consultation with the vendor, to submit an annual 494 495 report to the Governor and the Legislature by a 496 specified date; providing requirements for such 497 report; authorizing the agency to adopt rules; 498 providing an effective date.